Microbiota, probiotics and respiratory infections: the three musketeers can tip off potential management of COVID-19.

ABSTRACT: Rapid infectivity of SARS-CoV2 with recent viral variants is posing a challenge in the development of robust therapeutic strategies. On the other hand, microbiota is debated for its involvement in SARS-CoV2 infection with varied opinions. Although ample data about the role of microbiota and probiotics in respiratory viral infections are available, their role in COVID-19 is limited albeit emerging rapidly. The utilization of probiotics for the management of COVID-19 is still under investigation in many clinical trials. Existing information coupled with recent COVID-19 related studies can suggest various ways to use microbiota modulation and probiotics for managing this pandemic. Present article indicates the role of microbiota modulation and probiotics in respiratory infections. In addition

SUBMITTER: Khan AA 

PROVIDER: S-EPMC8581851 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature